Nivolumab + Ipilimumab Front Line bevacizumab atezolizumab

Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares thoughts on Nivoluma... Author: moasc Added: 03/06/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts